{name}
{subtitle}
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
city
~13 mi. (Hobart, Australia, +89 more cities)
facility
ICON Cancer Care Hobart
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +1 more drug
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
city
~13 mi. (Hobart, Australia, +151 more cities)
facility
GSK Investigational Site
drug
niraparib, +1 more drug
drug type
immunotherapy, +1 more type
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
city
~13 mi. (Hobart, Australia, +141 more cities)
facility
GSK Investigational Site
drug type
chemotherapy, +1 more type
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
city
~13 mi. (Hobart, Australia, +142 more cities)
facility
Royal Hobart Hospital
biomarker
del(11)(q10), +27 more biomarkers
drug
imetelstat, +1 more drug
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
city
~13 mi. (Hobart, Australia, +50 more cities)
facility
Royal Hobart Hospital
condition
B-Cell Non-Hodgkin Lymphoma, +1 more condition
drug
atezolizumab, +1 more drug
Tislelizumab Plus BGB-A1217 Versus Tislelizumab Versus Durvalumab When Co-administered With Concurrent Chemoradiotherapy (cCRT) in Lung Cancer
city
~13 mi. (Hobart, Australia, +7 more cities)
facility
Royal Hobart Hospital
drug
chemotherapy, +3 more drugs
drug type
chemotherapy, +1 more type